Zalicus Inc (NASDAQ:ZLCS) on June 18 announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in clinical and regulatory milestone payments and up to 12% of net sales on any future products resulting from this license. Zalicus Inc (NASDAQ:ZLCS) stock performance was -5.18% in last session and finished the day at $1.28. Traded volume was 501,953.00million shares in the last session and the average volume of the stock remained 841.25K shares. The beta of the stock remained 1.49. Zalicus Inc (NASDAQ:ZLCS) insider ownership is 2.40%.

Stemline Therapeutics Inc (NASDAQ:STML) revealed in its quarterly report on 15 May 2014 that company net loss from operations was $9.0 million for the three months ended March 31, 2014 and $5.5 million for the three months ended March 31, 2013. They expect to incur significant expenses and increasing operating losses for the foreseeable future. Stemline Therapeutics Inc (NASDAQ:STML) dropped -5.42 percent to $14.93 Thursday on volume of 139,304.00million shares. The intra-day range of the stock was $14.84 to $15.94. Stemline Therapeutics Inc (NASDAQ:STML) has a market capitalization of $197.67million.

Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced that Robert Stein, MD, PhD, the company’s Chief Scientific Officer, will present a company overview at the JMP Securities Healthcare Conference at the Westin Grand Central Hotel in New York City on Tuesday, June 24th at 12:30 pm ET. Agenus Inc (NASDAQ:AGEN)’s stock on June 19, 2014 reported a decrease of -5.87% to the closing price of $3.37. Its fifty two weeks range is $2.27 -$5.27. The total market capitalization recorded $209.74million. The overall volume in the last trading session was 496,887.00million shares. In its share capital, AGEN has 62.22million outstanding shares.

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes. On Thursday, shares of Arrowhead Research Corp (NASDAQ:ARWR) dropped -7.34% to close the day at $13.89. Company return on investment (ROI) is -82.60% and its monthly performance is recorded as 22.92%. Arrowhead Research Corp (NASDAQ:ARWR) quarterly revenue growth is -41.66%.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will receive $2.1 million in tax credits and has pledged to hire 180 employees and invest $16 million in its business; XCell Science, Inc. will get $20,000 in credits and has pledged to hire eight people and invest $213,103, according to the Governor’s Office of Business and Economic Development. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) stock performance was -8.36% in last session and finished the day at $44.60. Traded volume was 178,058.00million shares in the last session and the average volume of the stock remained 181.46K shares. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) insider ownership is 2.90%.